Targets › ITGAV
8 programs from 6 companies in 12 trials: 11 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Dec 2026.
The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling. (UniProt, P06756)
Open in Phaseline: the race on ITGAV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Erasmus Medical Center | cRGD-ZW800-1 RGD peptide-based fluorescent tracer targeting αvβ3 integrin | ITGAV, ITGB3 | Phase 2 | Squamous Cell Carcinoma of the Larynx | Mar 2028 |
| Corbus Pharmaceuticals | CRB-601 αvβ8 integrin antagonist monoclonal antibody | ITGAV, ITGB8 | Phase 1 | Solid Tumor | Dec 2026 |
| The First Affiliated Hospital of Xiamen University | 177Lu-AB-3PRGD2 Integrin αvβ3-targeting radioligand therapy (177Lu-labeled) | ITGAV, ITGB3 | Phase 1 | Refractory Solid Tumor | Dec 2026 |
| University of California, Davis | [18F]-αvβ6-BP Fluorine-18-labeled αvβ6 integrin-binding peptide for PET imaging | ITGAV, ITGB6 | Phase 1 | Lung Cancer | Dec 2026 |
| University of California, Davis | [68Ga]Ga DOTA-5G Integrin alphavbeta6 (αvβ6) targeting radioligand for PET imaging | ITGAV | Phase 1 | Metastatic Nonsmall Cell Lung Cancer; Metastatic Lobular Breast Carcinoma; Metastatic Cancer | Jan 2027 |
| Memorial Sloan Kettering Cancer Center | 89Zr-DFO-cRGDY-PEG-Cy5-C' dots Integrin αvβ3 targeting ultrasmall silica nanoparticle PET tracer | ITGAV | Phase 1 | Brain Cancer | Mar 2027 |
| Memorial Sloan Kettering Cancer Center | fluorescent cRGDY-PEG-Cy5.5-C dots RGD peptide-functionalized silica nanoparticles with fluorescent Cy5.5 dye for imaging int | ITGAV, ITGB3 | Phase 1 | Head and Neck Melanoma | Apr 2027 |
| Peking Union Medical College Hospital | 68Ga-RGD RGD peptide targeting integrin αvβ3 for PET imaging | ITGAV, ITGB3 | Phase 1 | Keloid | Oct 2027 |
Metastatic Nonsmall Cell Lung Cancer (2) Metastatic Cancer (2) Refractory Solid Tumor (1) Solid Tumor (1) Squamous Cell Carcinoma of the Larynx (1) Metastatic Lobular Breast Carcinoma (1) Head and Neck Melanoma (1) Brain Cancer (1) Keloid (1) Lung Cancer (1)
small molecule (7), antibody (1)
University of California, Davis (2) Memorial Sloan Kettering Cancer Center (2) The First Affiliated Hospital of Xiamen University (1) Corbus Pharmaceuticals (1) Erasmus Medical Center (1) Peking Union Medical College Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.